We investigated the cytotoxic effect of nitric oxide (NO) on primary culture of human hematological malignant cells. Sodium nitroprusside (SNP), an NO donor, had cytotoxic effects on the cells of some patients with malignant lymphoma (ML), acute myelocytic leukemia (AML) or chronic myelomonocytic leukemia (CMMoL), but not with multiple myeloma. Cultured cells from the ML patient remained sensitive to SNP after the cells became resistant to anti-cancer drugs. In contrast, the cells from the patients with AML and CMMoL became resistant to SNP while anti-cancer drugs remained effective. In samples of the cells of the patients with ML and AML, the number of CD3 positive lymphoma cell was decreased by SNP and the number of CD33 negative cells and normal B lymphocytes (CD19 positive cells) were increased. In the cells of the patient with ML, apoptosis was induced by SNP. SNP had no effect on lymphocytes of healthy volunteers. These results suggest that SNP had an anti-tumor effect on human hematological malignant cells.
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Nitric oxide (NO) is a multifunctional molecule produced in a variety of mammalian cells. At physiological levels, NO is associated with neurotransmission and vasodilatation. At higher levels, NO has tumoricidal and bacteriocidal effects [1, 2] . In the cell-mediated immune responses, NO is produced in macrophages, neutrophils and lymphocytes [3] [4] [5] [5] [6] [7] [8] [9] . These results raise the possibility that an NO donor might serve as a chemotherapeutic agent for hematological disorders. In the present study, we investigated the possibility of NO being a novel agent for the treatment of hematological malignancy using freshly isolated cells from patients with malignant hematological disorders.
EXPERIMENTAL PROCEDURES
Malignant cells were obtained from venous blood, bone marrow, ascites and lymphnodes of patients with malignant lymphoma (ML, n = 6), acute myelocytic leukemia (AML, n = 5), acute lymphocytic leukemia (ALL, n = 1), chronic myelomonocytic leukemia (CMMoL, n = 3) and multiple myeloma (MM, n = 2), who were hospitalized in Shimane Medical University Hospital (Izumo, Japan) (Table 1). As normal control, lymphocytes were collected from venous blood of healthy volunteers (n = 3). The collected cells were washed with phosphate buffered saline and layered on Histopaque-1077 (Sigma-Aldrich, Tokyo, Japan). After centrifugation at 1500 r.p.m. for 30 min, the cells present in the opaque interface were washed, plated (2-4´10 6 /ml) and cultured for 3-5 days before the experiments in RPMI 1640 medium supplemented with 10% fetal calf serum. Sodium nitroprusside (SNP) or anti-cancer drugs were added to the cells which were then cultured for 3 days. Next, the total viable cell number was measured by the MTT assay [10] and subpopulations of viable cells were ana- All results were expressed as means ± S.E.M. The significance of difference was evaluated by ANOVA and Fisher's test. A probability of P < 0.05 was considered statistically significant.
RESULTS
The effect of SNP on cultured cells from the patients with malignant blood disorders is shown in Table 1 . SNP reduced viability of the cells from 5 out of 6 patients with ML in a dose-related manner. SNP was effective with cells of one of 6 patients (AL, AML, ALL) with acute leukemia and one of 3 patients with CMMoL. In the patients with MM, 30 mM SNP showed cytotoxicity with the cells of Case 16 but 100 mM SNP had no effect. With Case 17, either dose of SNP had no effect on the cells. The lymphoma cells of Case 1 (ML) were sensitive to SNP even after becoming resistant to the anti-cancer drugs. In contrast, the cells of Case 10 (AML) and Case 14 (CMMoL) became resistant to SNP, while remaining sensitive to the anti-cancer drugs (Fig. 1) . Flow cytometry analysis revealed that SNP decreased the population of lymphoma cells (CD3 positive cells) of Case 5 (ML). In Case 4 (ML), SNP did not decrease the number of CD3 positive cells but increased that of normal lymphocytes (CD19 positive cells). In Case 10 (AML), SNP also increased the number of benign cells (CD33 negative cells) (Fig. 2) . SNP induced apoptosis of the cells of Case 5 (ML) in a dose-related manner. SNP (100 mM) showed cytotoxicity comparable to that of Ara-C (10 mg/ml) (Fig. 3) . SNP was not cytotoxic for normal lymphocytes of healthy volunteers as studied by the MTT assay and flow cytometry (Fig. 4) .
DISCUSSION
SNP showed cytotoxicity for the cells of ML patients independently cell type. The effect of SNP was most potent and persistent in the cells from the patients with ML, as compared with those with other hematological disorders. These results indicate that SNP is a promising candidate for an anti-lymphoma agent. However, out of 6 patients with AL, the Vol. 49 Nitric oxide effect on human hematological malignant cell 141 Cellular viability was expressed as % of corresponding control value. Open column, pre-chemotherapy; closed column, after chemotherapy. CPA, cyclophosphamide 1600 mg/ml. VCR, vincristine 6 mg/ml; Ara-C, cytosine arabinoside. *P < 0.05 vs. corresponding control value. cytotoxic effect of SNP was observed in only one case (Case 10). The specificity of the effect of SNP on leukemia cells remains to be clarified. Case 10 was at the most advanced stage of the decrease among the patients with AL and the youngest among all the examined patients. In samples of cells from the patients with leukemia (Case 7-15), the cytotoxic effect of SNP was weak and transient, and cytotoxicity of SNP towards the cells of patients with MM was unclear. According to the results of flow cytometry, SNP was not toxic to normal cells either of the patients with hematological diseases or healthy people. Thus, it is possible that SNP induces much less adverse effects as compared with anti-cancer drugs. Taken together, the results suggest that SNP could be used as a novel anticancer agent.
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